Spurned by FDA on another immunotherapy, Agenus holds up early data for CTLA-4 drug across tumor types

Kyle Blankenship

In a Phase I study across nine tumor types, Agenus’ CTLA-4 drug AGN1181 posted one complete response and three partial responses as a monotherapy, offering …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Spurned by FDA on another immunotherapy, Agenus holds up early data for CTLA-4 drug across tumor types

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Biogen offers to buy out struggling neuro partner Sage Therapeutics

Post-Hoc: Big Pharma is losing the AI talent war

Exclusive: Moderna's former top scientist has a new startup using AI to improve mRNA therapies

Chasing the next wave of obesity drugs, Metsera files for an IPO

Four biotechs emerge with $800M and in-licensed assets on Friday

Lilly finances new $500M biotech fund managed by a16z

Spurned by FDA on an­oth­er im­munother­a­py, Agenus holds up ear­ly da­ta for CT­LA-4 drug across tu­mor types

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Spurned by FDA on another immunotherapy, Agenus holds up early data for CTLA-4 drug across tumor types